Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
9.61
-0.55 (-5.41%)
Jun 26, 2026, 1:39 PM EDT - Market open
Adlai Nortye Revenue
In the year 2025, Adlai Nortye had annual revenue of $5.00M. Adlai Nortye had revenue of $5.00M in the half year ending December 31, 2025.
Revenue (ttm)
$5.00M
Revenue Growth
n/a
P/S Ratio
76.80
Revenue / Employee
$45,872
Employees
109
Market Cap
384.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 45.73M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Autolus Therapeutics | 92.62M |
| Editas Medicine | 38.69M |
| vTv Therapeutics | 36.84M |
| Prelude Therapeutics | 16.72M |
| Ovid Therapeutics | 7.12M |
| Shattuck Labs | 1.00M |
| Silence Therapeutics | 839.00K |
ANL News
- 4 days ago - Cantor starts Adlai Nortye at Overweight, sees 180% upside - TheFly
- 4 days ago - Adlai Nortye initiated with an Overweight at Cantor Fitzgerald - TheFly
- 22 days ago - Adlai Nortye Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Adlai Nortye initiated with an Outperform at Oppenheimer - TheFly
- 6 weeks ago - Adlai Nortye initiated with a Buy at JonesResearch - TheFly
- 2 months ago - Adlai Nortye Registration statement: Registration filing - Filings
- 2 months ago - Adlai Nortye Registration statement: Registration filing - Filings
- 2 months ago - Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright - TheFly